<DOC>
	<DOCNO>NCT03078738</DOCNO>
	<brief_summary>The aim first-in-human study ass safety , tolerability , PK exploratory pharmacodynamics ( PD ) single multiple oral ascend dos OMT-28 healthy male subject support clinical development OMT-28 indication atrial fibrillation ( AF ) obtain data food gender effect OMT-28 guide dose Phase II trial .</brief_summary>
	<brief_title>Safety Pharmacokinetic Study OMT-28 Healthy Subjects</brief_title>
	<detailed_description>This first-in-human study carry one study center involve multiple step . Up 100 healthy male female subject enrol . The study consist 4 part : 1. single ascend dose ( SAD ) part 2. multiple ascend dose ( MAD ) part 3. single dose , double cross-over food effect ( FE ) part . 4. single dose gender effect part ( female subject group ) The safety PK data evaluate DSMC cohort decide dose escalation .</detailed_description>
	<criteria>1 . In general good physical health determine medical surgical history , physical examination , 12 lead ECG , vital sign , clinical laboratory test 2 . Normal blood pressure ( Systolic Blood Pressure ( SBP ) 100 140 mmHg ( inclusive ) ; Diastolic Blood Pressure ( DBP ) ≥55 , ≤89 mmHg ) measure 5 min rest supine position . 3 . SAD , MAD , FE part : male 18 45 year ( inclusive ) age . 4 . Gender effect part : female 18 45 year ( inclusive ) age . 1 . More moderate smoker ( &gt; 10 cigarettes/day ) . 2 . More moderate alcohol consumption ( &gt; 35 g ethanol regularly per day &gt; 245 g regularly per week ) . 3 . Use medication 4 . One key safety laboratory parameter normal range Gender effect part Pregnant breastfeed woman childbearing potential Previous assignment treatment study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>OMT-28</keyword>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>SAD</keyword>
	<keyword>MAD</keyword>
	<keyword>First-in-Man</keyword>
	<keyword>Cardiovascular</keyword>
</DOC>